A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Netazepide (Primary)
- Indications Gastric atrophy; Gastric cancer; Gastritis; Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Trio Medicines
- 01 Aug 2018 Status changed from active, no longer recruiting to completed.
- 17 Oct 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 17 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.